PHF-tau Inhibitors
1 drugsAbout PHF-tau
PHF-tau, or paired helical filament tau, is a form of aggregated tau protein found in neurofibrillary tangles, which disrupt neuronal function and contribute to cognitive decline in diseases like Alzheimer's.
PHF-tau is a therapeutic target in the CNS to modify disease progression in devastating conditions like Alzheimer's, but there is currently no genetic evidence directly linking PHF-tau to specific diseases.
There is one FDA-approved drug, TAUVID, that targets PHF-tau, with a small molecule modality. AVID Radiopharmaceuticals Inc. is the only company with an approved drug for this target.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Substance Use Disorders with only 1 trials.
Top Drugs
AVID Radiopharmaceuticals Inc. is the only company with an approved drug targeting PHF-tau.
The lack of competition presents an opportunity for new entrants, but also indicates potential challenges in the target's validation.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PHF-tau, using small molecule modality.
Exploring alternative modalities like antibodies or gene therapies could provide a competitive advantage.
Clinical Trials 27 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 0 | 1 | 100% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
| Phase 3 | 7 | 6 | 0 | 1 | 100% |
| Phase 4 | 6 | 4 | 2 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2020 - 2020)
The first and most recent drug approval for PHF-tau was TAUVID in 2020.
The recent approval and lack of subsequent drugs suggest an emerging but not yet saturated market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (13 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 13 clinical trials targeting PHF-tau.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities